Viracta Therapeutics

VIRXPhase 2

San Diego, United StatesFounded 2005viracta.com

Viracta Therapeutics is pioneering a precision oncology approach to treat virus-associated cancers, with a primary focus on Epstein-Barr virus (EBV)-positive malignancies. The company's proprietary platform combines a viral activator with targeted anticancer agents to selectively induce viral lytic activation in cancer cells. Its lead candidate, nanatinostat in combination with valganciclovir, is in late-stage development for EBV-positive lymphomas and nasopharyngeal carcinoma. Viracta aims to address significant unmet medical needs in oncology through its novel mechanism of action.

Market Cap

$380K

Founded

2005

Employees

50-100

Focus

Biotech

AI Company Overview

Technology Platform

Proprietary lytic induction therapy platform combining viral activators with antiviral prodrugs to selectively target virus-associated cancer cells while sparing normal cells.

Pipeline Snapshot

3 drugs in pipeline

Drug	Indication	Stage
Nanatinostat in combination with valganciclovir	Epstein-Barr Virus Associated Lymphoma	Phase 2
Nanatinostat + Valganciclovir + Pembrolizumab	Nasopharyngeal Carcinoma	Phase 1
[14C]-Nanatinostat + Nanatinostat (free base) tablets in combination with Valgan...	Advanced Cancer	Phase 1

Opportunities

Significant market opportunity in EBV-associated cancers affecting thousands of patients annually, with potential for platform expansion to other virus-associated malignancies.

Combination strategies with immunotherapies could enhance efficacy and expand addressable patient populations.

Risk Factors

Clinical development risks including failure to demonstrate sufficient efficacy or acceptable safety, limited cash runway requiring additional financing, and regulatory challenges in obtaining approvals for novel combination therapies.

Competitive Landscape

Limited direct competition in EBV-targeted therapy space, but faces competition from standard chemotherapy, immunotherapy, and other targeted approaches for lymphoma and solid tumors. Differentiation lies in novel mechanism targeting viral component of cancer cells.